Why Inovio Stock Slid Today
Shares of Inovio Pharmaceuticals (NASDAQ: INO) were sliding 5.2% lower as of 3:45 p.m. EST on Friday. The company announced earlier in the day that positive results from a phase 2 study evaluating INO-5401 and INO-9012 in combination with cancer immunotherapy Libtayo will be presented at the Society for Neuro-Oncology (SNO) 2020 Annual Meeting. In addition, investors appear to be much more heavily focused on Inovio's COVID-19 program than anything else right now.